The case for beta-blockers as first-line antihypertensive therapy

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Management

Background:

• Asymptomatic hypertension treatment aims to prevent cardiovascular events like myocardial infarction, stroke, and heart failure.
• Established evidence supports diuretics and beta-blockers for reducing morbidity and mortality in hypertensive individuals.
• Cost-effectiveness favors diuretics and beta-blockers over newer antihypertensive agents.

Purpose of the Study:

• To review the efficacy and patient-specific benefits of different antihypertensive drug classes.
• To evaluate the impact of diuretics, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors on hard endpoints.
• To differentiate appropriate patient profiles for specific antihypertensive treatments.

Main Methods:

• Review of clinical trial data and established guidelines on antihypertensive treatment.
• Analysis of drug effects on hard endpoints (morbidity, mortality) versus surrogate markers.
• Categorization of drug suitability based on patient demographics and comorbidities.

Main Results:

• Diuretics and beta-blockers are the only drug classes proven to improve hard endpoints in hypertension.
• Diuretics are suitable for elderly patients, especially with isolated systolic hypertension, but may increase cardiac events in younger diabetics.
• Beta-blockers are beneficial for younger and middle-aged patients, particularly white males, and in cases of ischemia or stress, reducing myocardial infarction and stroke incidence.

Conclusions:

• Diuretics and beta-blockers offer proven benefits and cost-effectiveness for managing asymptomatic hypertension.
• Patient profiling is crucial; diuretics suit elderly patients, while beta-blockers are ideal for younger/middle-aged individuals, especially with cardiovascular risk factors.
• Angiotensin-converting enzyme (ACE) inhibitors show value in specific conditions like left ventricular dysfunction and diabetic nephropathy.